HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Q1

This article was originally published in The Rose Sheet

Executive Summary

Direct-seller anticipates double-digit growth in its beauty division will resume in the second quarter and continue through the end of the year, CEO Andrea Jung says during a Q1 analyst call May 2. Category will be driven by new product introductions in the second half of the year, such as Avon Color Shine Supreme lipstick, which is slated to bow in Q4, Jung adds. Avon's U.S. beauty business struggled in Q1, with sales down 10%, due to a tough comparison with the prior year and the timing of product innovation, according to the firm. U.S. revenue fell 6% to $516.5 mil. in the quarter, while operating profit was down 15% to $76.7 mil. Worldwide beauty division sales grew 8% to $1.3 bil., with personal care sales up 11%, color cosmetics up 8%, fragrance growing 8% and skin care increasing 4%. Avon's net sales increased 6.9% to $1.86 bil., while net income grew 16.1% to $172 mil...

You may also be interested in...



Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel